TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce its participation in a series of prestigious conferences this October. These events will showcase the Company’s advancements in exosome therapy, reinforce its commitment to driving innovation in regenerative medicine, and increase visibility with major pharmaceutical companies.
In October, NurExone will sponsor and present at the World Orphan Drug Congress in Barcelona from October 22-25, 2024. This prominent event unites global leaders in orphan drug development and rare diseases with a focus on strategy, advocacy and partnerships. NurExone will highlight its cutting-edge work in exosome-based therapies aimed at regeneration of neurons in the central nervous system leading to recovery of motor function after acute spinal cord injuries. Notably, NurExone is one of a small number of companies to receive Orphan Drug Designation for acute spinal cord injury.ii